Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMJ995 in Acute Lymphoblastic Leukemia
NCT05168748Phase 1Withdrawn
- Sponsor
- Novartis
- Start
- Jan 2023
- Primary completion
- Aug 2026
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of IMJ995 in acute lymphoblastic leukemia (ALL), sponsored by Novartis. Primary endpoints: Incidence and nature of Dose Limiting Toxicities at 28 days, Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) at 24 months and 1 more. Planned start Jan 2023; status: withdrawn.
02
Drugs
IMJ995
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05168748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05168748.